المؤلفون: Kang, Eun‐Young, Weir, Ashley, Meagher, Nicola S, Farrington, Kyo, Nelson, Gregg S, Ghatage, Prafull, Lee, Cheng‐Han, Riggan, Marjorie J, Bolithon, Adelyn, Popovic, Gordana, Leung, Betty, Tang, Katrina, Lambie, Neil, Millstein, Joshua, Alsop, Jennifer, Anglesio, Michael S, Ataseven, Beyhan, Barlow, Ellen, Beckmann, Matthias W, Berger, Jessica, Bisinotto, Christiani, Bösmüller, Hans, Boros, Jessica, Brand, Alison H, Brooks‐Wilson, Angela, Brucker, Sara Y, Carney, Michael E, Casablanca, Yovanni, Cazorla‐Jiménez, Alicia, Cohen, Paul A, Conrads, Thomas P, Cook, Linda S, Coulson, Penny, Courtney‐Brooks, Madeleine, Cramer, Daniel W, Crowe, Philip, Cunningham, Julie M, Cybulski, Cezary, Darcy, Kathleen M, El‐Bahrawy, Mona A, Elishaev, Esther, Erber, Ramona, Farrell, Rhonda, Fereday, Sian, Fischer, Anna, García, María J, Gayther, Simon A, Gentry‐Maharaj, Aleksandra, Gilks, C Blake, Group, AOCS, Grube, Marcel, Harnett, Paul R, Harrington, Shariska Petersen, Harter, Philipp, Hartmann, Arndt, Hecht, Jonathan L, Heikaus, Sebastian, Hein, Alexander, Heitz, Florian, Hendley, Joy, Hernandez, Brenda Y, Polo, Susanna Hernando, Heublein, Sabine, Hirasawa, Akira, Høgdall, Estrid, Høgdall, Claus K, Horlings, Hugo M, Huntsman, David G, Huzarski, Tomasz, Jewell, Andrea, Jimenez‐Linan, Mercedes, Jones, Michael E, Kaufmann, Scott H, Kennedy, Catherine J, Khabele, Dineo, Kommoss, Felix KF, Kruitwagen, Roy FPM, Lambrechts, Diether, Le, Nhu D, Lener, Marcin, Lester, Jenny, Leung, Yee, Linder, Anna, Loverix, Liselore, Lubiński, Jan, Madan, Rashna, Maxwell, G Larry, Modugno, Francesmary, Neuhausen, Susan L, Olawaiye, Alexander, Olbrecht, Siel, Orsulic, Sandra, Palacios, José, Pearce, Celeste Leigh, Pike, Malcolm C, Quinn, Carmel M, Mohan, Ganendra Raj, Rodríguez‐Antona, Cristina, Ruebner, Matthias, Ryan, Andy

المصدر: Cancer, vol 129, iss 5

مصطلحات موضوعية: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Ovarian Cancer, Rare Diseases, 2.1 Biological and endogenous factors, Aetiology, Female, Humans, Ovarian Neoplasms, Transcription Factors, Carcinoma, RNA, Messenger, Cystadenocarcinoma, Serous, Oncogene Proteins, Cyclin E, CCNE1 amplification, cyclin E1 expression, high-grade serous carcinoma, prognosis, AOCS Group, Public Health and Health Services, Oncology & Carcinogenesis, Public health

جغرافية الموضوع: 697 - 713

وصف الملف: application/pdf

العلاقة: qt6cm6k1w1; https://escholarship.org/uc/item/6cm6k1w1Test

الإتاحة: https://escholarship.org/uc/item/6cm6k1w1Test

المؤلفون: Kang, Eun-Young, Weir, Ashley, Meagher, Nicola S., Farrington, Kyo, Nelson, Gregg S., Ghatage, Prafull, Lee, Cheng-Han, Riggan, Marjorie J., Bolithon, Adelyn, Popovic, Gordana, Leung, Betty, Tang, Katrina, Lambie, Neil, Millstein, Joshua, Alsop, Jennifer, Anglesio, Michael S., Ataseven, Beyhan, Barlow, Ellen, Beckmann, Matthias W., Berger, Jessica, Bisinotto, Christiani, Bösmüller, Hans, Boros, Jessica, Brand, Alison H., Brooks-Wilson, Angela, Brucker, Sara Y., Carney, Michael E., Casablanca, Yovanni, Cazorla-Jiménez, Alicia, Cohen, Paul A., Conrads, Thomas P., Cook, Linda S., Coulson, Penny, Courtney-Brooks, Madeleine, Cramer, Daniel W., Crowe, Philip, Cunningham, Julie M., Cybulski, Cezary, Darcy, Kathleen M., El-Bahrawy, Mona A., Elishaev, Esther, Erber, Ramona, Farrell, Rhonda, Fereday, Sian, Fischer, Anna, García, María J., Gayther, Simon A., Gentry-Maharaj, Aleksandra, Gilks, C. Blake, Grube, Marcel, Harnett, Paul R., Harrington, Shariska Petersen, Harter, Philipp, Hartmann, Arndt, Hecht, Jonathan L., Heikaus, Sebastian, Hein, Alexander, Heitz, Florian, Hendley, Joy, Hernandez, Brenda Y., Polo, Susanna Hernando, Heublein, Sabine, Hirasawa, Akira, Høgdall, Estrid, Høgdall, Claus K., Horlings, Hugo M., Huntsman, David G., Huzarski, Tomasz, Jewell, Andrea, Jimenez-Linan, Mercedes, Jones, Michael E., Kaufmann, Scott H., Kennedy, Catherine J., Khabele, Dineo, Kommoss, Felix K. F., Kruitwagen, Roy F. P. M., Lambrechts, Diether, Le, Nhu D., Lener, Marcin, Lester, Jenny, Leung, Yee, Linder, Anna, Loverix, Liselore, Lubiński, Jan, Madan, Rashna, Maxwell, G. Larry, Modugno, Francesmary, Neuhausen, Susan L., Olawaiye, Alexander, Olbrecht, Siel, Orsulic, Sandra, Palacios, José, Pearce, Celeste Leigh, Pike, Malcolm C., Quinn, Carmel M., Mohan, Ganendra Raj, Rodríguez-Antona, Cristina, Ruebner, Matthias, Ryan, Andy, Salfinger, Stuart G., Sasamoto, Naoko, Schildkraut, Joellen M., Schoemaker, Minouk J., Shah, Mitul, Sharma, Raghwa, Shvetsov, Yurii B., Singh, Naveena, Sonke, Gabe S., Steele, Linda, Stewart, Colin J. R., Sundfeldt, Karin, Swerdlow, Anthony J., Talhouk, Aline, Tan, Adeline, Taylor, Sarah E., Terry, Kathryn L., Tołoczko, Aleksandra, Traficante, Nadia, Vijver, Koen K., Aa, Maaike A., Gorp, Toon, Nieuwenhuysen, Els, Van-Wagensveld, Lilian, Vergote, Ignace, Vierkant, Robert A., Wang, Chen, Wilkens, Lynne R., Winham, Stacey J., Wu, Anna H., Benitez, Javier, Berchuck, Andrew, Candido dos Reis, Francisco J., DeFazio, Anna, Fasching, Peter A., Goode, Ellen L., Goodman, Marc T., Gronwald, Jacek, Karlan, Beth Y., Kommoss, Stefan, Menon, Usha, Sinn, Hans-Peter, Staebler, Annette, Brenton, James D., Bowtell, David D., Pharoah, Paul D. P., Ramus, Susan J., Köbel, Martin

مصطلحات موضوعية: prognosis, ovarian cancer, high-grade serous carcinoma, cyclin E1 expression, CCNE1 amplification, Public Health, Oncology and Hematology, Health Sciences

وصف الملف: application/pdf

العلاقة: Kang, Eun-Young; Weir, Ashley; Meagher, Nicola S.; Farrington, Kyo; Nelson, Gregg S.; Ghatage, Prafull; Lee, Cheng-Han; Riggan, Marjorie J.; Bolithon, Adelyn; Popovic, Gordana; Leung, Betty; Tang, Katrina; Lambie, Neil; Millstein, Joshua; Alsop, Jennifer; Anglesio, Michael S.; Ataseven, Beyhan; Barlow, Ellen; Beckmann, Matthias W.; Berger, Jessica; Bisinotto, Christiani; Bösmüller, Hans; Boros, Jessica; Brand, Alison H.; Brooks-Wilson, Angela; Brucker, Sara Y.; Carney, Michael E.; Casablanca, Yovanni; Cazorla-Jiménez, Alicia; Cohen, Paul A.; Conrads, Thomas P.; Cook, Linda S.; Coulson, Penny; Courtney-Brooks, Madeleine; Cramer, Daniel W.; Crowe, Philip; Cunningham, Julie M.; Cybulski, Cezary; Darcy, Kathleen M.; El-Bahrawy, Mona A.; Elishaev, Esther; Erber, Ramona; Farrell, Rhonda; Fereday, Sian; Fischer, Anna; García, María J.; Gayther, Simon A.; Gentry-Maharaj, Aleksandra; Gilks, C. Blake; Grube, Marcel; Harnett, Paul R.; Harrington, Shariska Petersen; Harter, Philipp; Hartmann, Arndt; Hecht, Jonathan L.; Heikaus, Sebastian; Hein, Alexander; Heitz, Florian; Hendley, Joy; Hernandez, Brenda Y.; Polo, Susanna Hernando; Heublein, Sabine; Hirasawa, Akira; Høgdall, Estrid; Høgdall, Claus K.; Horlings, Hugo M.; Huntsman, David G.; Huzarski, Tomasz; Jewell, Andrea; Jimenez-Linan, Mercedes; Jones, Michael E.; Kaufmann, Scott H.; Kennedy, Catherine J.; Khabele, Dineo; Kommoss, Felix K. F.; Kruitwagen, Roy F. P. M.; Lambrechts, Diether; Le, Nhu D.; Lener, Marcin; Lester, Jenny; Leung, Yee; Linder, Anna; Loverix, Liselore; Lubiński, Jan; Madan, Rashna; Maxwell, G. Larry; Modugno, Francesmary; Neuhausen, Susan L.; Olawaiye, Alexander; Olbrecht, Siel; Orsulic, Sandra; Palacios, José; Pearce, Celeste Leigh; Pike, Malcolm C.; Quinn, Carmel M.; Mohan, Ganendra Raj; Rodríguez-Antona, Cristina; Ruebner, Matthias; Ryan, Andy; Salfinger, Stuart G.; Sasamoto, Naoko; Schildkraut, Joellen M.; Schoemaker, Minouk J.; Shah, Mitul; Sharma, Raghwa; Shvetsov, Yurii B.; Singh, Naveena; Sonke, Gabe S.; Steele, Linda; Stewart, Colin J. R.; Sundfeldt, Karin; Swerdlow, Anthony J.; Talhouk, Aline; Tan, Adeline; Taylor, Sarah E.; Terry, Kathryn L.; Tołoczko, Aleksandra; Traficante, Nadia; Vijver, Koen K.; Aa, Maaike A.; Gorp, Toon; Nieuwenhuysen, Els; Van-Wagensveld, Lilian; Vergote, Ignace; Vierkant, Robert A.; Wang, Chen; Wilkens, Lynne R.; Winham, Stacey J.; Wu, Anna H.; Benitez, Javier; Berchuck, Andrew; Candido dos Reis, Francisco J.; DeFazio, Anna; Fasching, Peter A.; Goode, Ellen L.; Goodman, Marc T.; Gronwald, Jacek; Karlan, Beth Y.; Kommoss, Stefan; Menon, Usha; Sinn, Hans-Peter; Staebler, Annette; Brenton, James D.; Bowtell, David D.; Pharoah, Paul D. P.; Ramus, Susan J.; Köbel, Martin (2023). "CCNE1 and survival of patients with tubo- ovarian high- grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study." Cancer 129(5): 697-713.; https://hdl.handle.net/2027.42/175893Test; Cancer; Lheureux S, Cristea MC, Bruce JP, et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021; 397 ( 10271 ): 281 - 292. doi:10.1016/s0140-6736(20)32554-x; Gallo D, Young JTF, Fourtounis J, et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature. 2022; 604 ( 7907 ): 749 - 756. doi:10.1038/s41586-022-04638-9; Caldon CE, Musgrove EA. Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer. Cell Div. 2010; 5 ( 1 ): 2. doi:10.1186/1747-1028-5-2; Lacey KR, Jackson PK, Stearns T. Cyclin-dependent kinase control of centrosome duplication. Proc National Acad Sci USA. 1999; 96 ( 6 ): 2817 - 2822. doi:10.1073/pnas.96.6.2817; Koff A, Giordano A, Desai D, et al. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science. 1992; 257 ( 5077 ): 1689 - 1694. doi:10.1126/science.1388288; Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature. 1999; 401 ( 6750 ): 297 - 300. doi:10.1038/45836; Bester AC, Roniger M, Oren YS, et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell. 2011; 145 ( 3 ): 435 - 446. doi:10.1016/j.cell.2011.03.044; Karst AM, Jones PM, Vena N, et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res. 2014; 74 ( 4 ): 1141 - 1152. doi:10.1158/0008-5472.can-13-2247; Etemadmoghadam D, de Fazio A, Beroukhim R, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res. 2009; 15 ( 4 ): 1417 - 1427. doi:10.1158/1078-0432.ccr-08-1564; Au-Yeung G, Lang F, Azar WJ, et al. Selective targeting of cyclin E1-amplified high-grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition. Clin Cancer Res. 2017; 23 ( 7 ): 1862 - 1874. doi:10.1158/1078-0432.ccr-16-0620; Geng Y, Michowski W, Chick JM, et al. Kinase-independent function of E-type cyclins in liver cancer. Proc National Acad Sci USA. 2018; 115 ( 5 ): 1015 - 1020. doi:10.1073/pnas.1711477115; Au-Yeung G, Bressel M, Prall O, et al. A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification. J Clin Oncol. 2022; 40 ( 16_suppl ): 5515. doi:10.1200/jco.2022.40.16_suppl.5515; Gorski JW, Ueland FR, Kolesar JM. CCNE1 amplification as a predictive biomarker of chemotherapy resistance in epithelial ovarian cancer. Diagnostics. 2020; 10 ( 5 ): 279. doi:10.3390/diagnostics10050279; Nakayama N, Nakayama K, Shamima Y, et al. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer. 2010; 116: 2621 - 2634. doi:10.1002/cncr.24987; Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474 ( 7353 ): 609 - 615. doi:10.1038/nature10166; Stronach EA, Paul J, Timms KM, et al. Biomarker assessment of HR deficiency, tumor BRCA1/2 mutations, and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy. Mol Cancer Res. 2018; 16 ( 7 ): 1103 - 1111. doi:10.1158/1541-7786.mcr-18-0034; Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2 ( 5 ): 401 - 404. doi:10.1158/2159-8290.cd-12-0095; Etemadmoghadam D, Weir BA, Au-Yeung G, et al. Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc National Acad Sci USA. 2013; 110 ( 48 ): 19489 - 19494. doi:10.1073/pnas.1314302110; Chan AM, Enwere E, McIntyre JB, et al. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma. J Pathol Clin Res. 2020; 6 ( 4 ): 252 - 262. doi:10.1002/cjp2.168; Macintyre G, Goranova TE, De Silva D, et al. Copy number signatures and mutational processes in ovarian carcinoma. Nat Genet. 2018; 50 ( 9 ): 1262 - 1270. doi:10.1038/s41588-018-0179-8; Vázquez-García I, Uhlitz F, Ceglia N, et al. Immune and malignant cell phenotypes of ovarian cancer are determined by distinct mutational processes. bioRxiv. 2021.; González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019; 381 ( 25 ): 2391 - 2402. doi:10.1056/nejmoa1910962; Millstein J, Budden T, Goode EL, et al. Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol. 2020; 31: 1240 - 1250.; Farley J, Smith LM, Darcy KM, et al. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res. 2003; 63: 1235 - 1241.; Wang X, Qi X, Ming X, Wang L, Wang Y, Zhao X. Prognostic value of cyclin E expression in patients with ovarian cancer: a meta-analysis. J BUON. 2017; 22: 64 - 71.; Köbel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008; 5 ( 12 ): e232. doi:10.1371/journal.pmed.0050232; Aziz D, Etemadmoghadam D, Caldon CE, et al. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes. Gynecol Oncol. 2018; 151 ( 2 ): 327 - 336. doi:10.1016/j.ygyno.2018.08.039; Sieh W, Köbel M, Longacre TA, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013; 14: 853 - 862.; Köbel M, Kalloger SE, Lee S, et al. Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomark Prev. 2013; 22 ( 10 ): 1677 - 1686. doi:10.1158/1055-9965.epi-13-0391; Rambau PF, Vierkant RA, Intermaggio MP, et al. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. J Pathol Clin Res. 2018; 4: 250 - 261. doi:10.1002/cjp2.109; Garsed DW, Alsop K, Fereday S, et al. Homologous recombination DNA repair pathway disruption and retinoblastoma protein loss are associated with exceptional survival in high-grade serous ovarian cancer. Clin Cancer Res. 2018; 24 ( 3 ): 569 - 580. doi:10.1158/1078-0432.ccr-17-1621; Kang EY, Millstein J, Popovic G, et al. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Arch. 2022; 480: 855 - 871.; Talhouk A, Kommoss S, Mackenzie R, et al. Single-patient molecular testing with NanoString nCounter data using a reference-based strategy for batch effect correction. PLoS One. 2016; 11 ( 4 ): e0153844. doi:10.1371/journal.pone.0153844; Talhouk A, George J, Wang C, et al. Development and validation of the gene expression predictor of high-grade serous ovarian carcinoma molecular SubTYPE (PrOTYPE). Clin Cancer Res. 2020; 26: 5411 - 5423.; Köbel M, Piskorz AM, Lee S, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res. 2016; 2 ( 4 ): 247 - 258. doi:10.1002/cjp2.53; Kanska J, Zakhour M, Taylor-Harding B, Karlan BY, Wiedemeyer WR. Cyclin E as a potential therapeutic target in high grade serous ovarian cancer. Gynecol Oncol. 2016; 143 ( 1 ): 152 - 158. doi:10.1016/j.ygyno.2016.07.111; Lepage CC, Palmer MCL, Farrell AC, et al. Reduced SKP1 and CUL1 expression underlies increases in cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer. Br J Cancer. 2021; 124 ( 10 ): 1699 - 1710. doi:10.1038/s41416-021-01317-w; Spruck C, Sun D, Fiegl H, et al. Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer. Cancer Res. 2006; 66 ( 14 ): 7355 - 7360. doi:10.1158/0008-5472.can-05-3240; Theurillat JP, Metzler SC, Henzi N, et al. URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell. 2011; 19 ( 3 ): 317 - 332. doi:10.1016/j.ccr.2011.01.019; Lee JM, Minasian L, Kohn EC. New strategies in ovarian cancer treatment. Cancer. 2019; 125 ( suppl 24 ): 4623 - 4629. doi:10.1002/cncr.32544

الإتاحة: https://doi.org/10.1002/cncr.34582Test
https://doi.org/10.1016/s0140-6736Test(20)32554-x
https://doi.org/10.1038/s41586-022-04638-9Test
https://doi.org/10.1186/1747-1028-5-2Test
https://doi.org/10.1073/pnas.96.6.2817Test
https://doi.org/10.1126/science.1388288Test
https://doi.org/10.1038/45836Test
https://doi.org/10.1016/j.cell.2011.03.044Test
https://doi.org/10.1158/0008-5472.can-13-2247Test
https://doi.org/10.1158/1078-0432.ccr-08-1564Test

المؤلفون: Rambau, Peter F, Vierkant, Robert A, Intermaggio, Maria P, Kelemen, Linda E, Goodman, Marc T, Herpel, Esther, Pharoah, Paul D, Kommoss, Stefan, Jimenez‐Linan, Mercedes, Karlan, Beth Y, Gentry‐Maharaj, Aleksandra, Menon, Usha, Polo, Susanna Hernando, dos Reis, Francisco J Candido, Doherty, Jennifer Anne, Gayther, Simon A, Sharma, Raghwa, Larson, Melissa C, Harnett, Paul R, Hatfield, Emma, de Andrade, Jurandyr M, Nelson, Gregg S, Steed, Helen, Schildkraut, Joellen M, Carney, Micheal E, Høgdall, Estrid, Whittemore, Alice S, Widschwendter, Martin, Kennedy, Catherine J, Wang, Frances, Wang, Qin, Wang, Chen, Armasu, Sebastian M, Daley, Frances, Coulson, Penny, Jones, Micheal E, Anglesio, Micheal S, Chow, Christine, de Fazio, Anna, García‐Closas, Montserrat, Brucker, Sara Y, Cybulski, Cezary, Harris, Holly R, Hartkopf, Andreas D, Huzarski, Tomasz, Jensen, Allan, Lubiński, Jan, Oszurek, Oleg, Benitez, Javier, Mina, Fady, Staebler, Annette, Taran, Florin Andrei, Pasternak, Jana, Talhouk, Aline, Rossing, Mary Anne, Hendley, Joy, Group, AOCS, Edwards, Robert P, Fereday, Sian, Modugno, Francesmary, Ness, Roberta B, Sieh, Weiva, El‐Bahrawy, Mona A, Winham, Stacey J, Lester, Jenny, Kjaer, Susanne K, Gronwald, Jacek, Sinn, Peter, Fasching, Peter A, Chang‐Claude, Jenny, Moysich, Kirsten B, Bowtell, David D, Hernandez, Brenda Y, Luk, Hugh, Behrens, Sabine, Shah, Mitul, Jung, Audrey, Ghatage, Prafull, Alsop, Jennifer, Alsop, Kathryn, García‐Donas, Jesús, Thompson, Pamela J, Swerdlow, Anthony J, Karpinskyj, Chloe, Cazorla‐Jiménez, Alicia, García, María J, Deen, Susha, Wilkens, Lynne R, Palacios, José, Berchuck, Andrew, Koziak, Jennifer M, Brenton, James D, Cook, Linda S, Goode, Ellen L, Huntsman, David G, Ramus, Susan J, Köbel, Martin

المصدر: The Journal of Pathology Clinical Research, vol 4, iss 4

مصطلحات موضوعية: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Cancer, Ovarian Cancer, Genetics, 2.1 Biological and endogenous factors, Aetiology, Adenocarcinoma, Mucinous, Adult, Aged, Cyclin-Dependent Kinase Inhibitor p16, Cystadenocarcinoma, Serous, Female, Humans, Immunohistochemistry, Middle Aged, Ovarian Neoplasms, Ovary, Prognosis, Survival Rate, immunocytochemistry, RT-QPCR, AOCS Group, Clinical sciences

جغرافية الموضوع: 250 - 261

العلاقة: qt2k43648v; https://escholarship.org/uc/item/2k43648vTest

الإتاحة: https://escholarship.org/uc/item/2k43648vTest